Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07361432
Eligibility Criteria:
Inclusion Criteria:
* an ICD-11 OUD diagnosis in the VHA electronic health record (EHR)
* receipt of buprenorphine from outpatient addiction clinic with stable (i.e., unchanged in 2 weeks or since last injection) dose confirmed by the prescribing clinician. Both oral and injectable buprenorphine formulations will be eligible with dose stabilization required to isolate chronic pain from withdrawal-related pain associated with non-therapeutic dose
* presence of musculoskeletal pain that is bothersome or high-impact per the Graded Pain Scale - Revised
* access to a web-connected device to complete daily surveys and connect to IMPACT treatment site
* ability to participate safely in the walking portion of the intervention as evidenced by patient-reported ability to walk at least one block
Exclusion Criteria:
* dementia-related EHR diagnosis
* participant-reported vision or hearing impairments that would preclude use of the IMPACT system
* legal actions that would make study completion unlikely
* current or past 12 month engagement in CBT for chronic pain treatment
* planned surgical intervention for pain
* physical or mental health conditions that would interfere with ability to meaningful engage in IMPACT and MOUD treatment (e.g., uncontrolled bipolar disorder, active suicidal ideation, receipt of hospice or end-of-life palliative care)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07361432
Study Brief:
Protocol Section:
NCT07361432